Busulfan, the corner stone of hematopoietic stem cell transplantation regimens, has a narrow therapeutic window. Therapeutic drug monitoring (TDM)-guided dosing to reach the conventional area unde ...

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide ...

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget. ABT199 ...